Tevogen Bio CEO Dr. Ryan Saadi named to 2025 NJBIZ Power 100

From GlobeNewswire: 2025-02-28 13:17:46

Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, announced its Founder and CEO, Ryan Saadi, MD, MPH, was named to the 2025 NJBIZ Power 100 for shaping NJ’s business landscape. Tevogen’s ExacTcell technology enabled a successful proof-of-concept trial published in Blood Advances. To improve accessibility, Tevogen launched Tevogen.AI and partnered with Microsoft. The company focuses on developing affordable, safe T cell therapies for viral infections and cancers. Their mission is to challenge rising drug development costs with an efficient business model prioritizing affordability and accessibility. Tevogen Bio’s positive safety data from clinical trials and key patents support their innovative approach.



Read more at GlobeNewswire: Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025